MARKET

VXRT

VXRT

Vaxart Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.345
+0.185
+5.85%
Opening 10:13 05/19 EDT
OPEN
3.130
PREV CLOSE
3.160
HIGH
3.400
LOW
3.080
VOLUME
727.57K
TURNOVER
1.31M
52 WEEK HIGH
10.33
52 WEEK LOW
2.490
MARKET CAP
422.96M
P/E (TTM)
-5.2257
1D
5D
1M
3M
1Y
5Y
Vaxart Announces The Publication Of Studies In The Peer-reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease COVID Transmission
Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission A preclinical study in hamsters showed
Benzinga · 10h ago
Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission
A preclinical study in hamsters showed both a decrease in infectious virus and in transmission Phase 1 data measuring cross-reactivity also included in the publication SOUTH SAN FRANCISCO, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Science Translational Medi...
GlobeNewswire · 10h ago
Here's why meme stocks are hinting at another flashy rally for `junk stocks`
We've seen this movie before only to watch dip-buyers get fleeced — but money managers are now warming to the idea of a material bounce in stocks.
Yahoo Finance · 6d ago
Vaxart names interim CFO, search underway for permanent role
Vaxart (NASDAQ:VXRT) announced that it is retaining Fuad Ahmad, a partner at FLG, a CFO services and board advisory consulting firm, as its interim CFO and a non-employee consultant. The company
Seekingalpha · 05/12 12:22
BRIEF-Vaxart Retained Fuad Ahmad As Co's Interim CFO, Search Ongoing For CFO
reuters.com · 05/11 21:42
Plug Power, Upstart Holdings, Affirm Holdings among premarket losers' pack
Upstart Holdings (UPST) -54% on Q1 earnings release. GoodRx Holdings (GDRX) -35% on Q1 earnings release. Bausch Health Companies (BHC) -33% on Q1 earnings release. Peloton Interactive (PTON) -24% on FQ3 earnings release. Novavax (NVAX) -22% on Q1 earnings ...
Seekingalpha · 05/10 12:28
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Investor Place · 05/10 11:25
Vaxart Q1 Net Loss Widens as Revenue Declines
MT Newswires · 05/10 04:58
More
No Data
Learn about the latest financial forecast of VXRT. Analyze the recent business situations of Vaxart Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

20.00%Strong Buy
60.00%Buy
20.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VXRT stock price target is 11.60 with a high estimate of 18.00 and a low estimate of 7.00.
High18.00
Average11.60
Low7.00
Current 3.520
EPS
Actual
Estimate
-0.17-0.13-0.08-0.04
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 170
Institutional Holdings: 43.87M
% Owned: 34.70%
Shares Outstanding: 126.45M
TypeInstitutionsShares
Increased
47
6.17M
New
28
1.23M
Decreased
41
1.04M
Sold Out
21
999.70K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.00%
Pharmaceuticals & Medical Research
+0.51%
Key Executives
Non-Executive Chairman/Independent Director
Todd Davis
President/Chief Executive Officer/Director
Andrei Floroiu
Chief Financial Officer
Fuad Ahmad
Senior Vice President/Chief Scientific Officer
Sean Tucker
Independent Director
Julie Cherrington
Independent Director
Michael Finney
Independent Director
David Wheadon
Independent Director
Karen Wilson
Independent Director
Robert Yedid
No Data
No Data
About VXRT
Vaxart, Inc. is a clinical-stage biotechnology company. It is focused on developing oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its oral vaccines are designed to generate immune responses that protect against a range of infectious diseases and will be useful for the treatment of chronic viral infections and cancer. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). It is also developing therapeutic vaccine targeting cervical cancer and dysplasia caused by human papillomavirus (HPV). Its therapeutic oral vaccine candidate targets HPV-16 and HPV-18, the two strains responsible for cervical cancers and precancerous cervical dysplasia. It uses a short section of double-stranded ribonucleic acid RNA (dsRNA) as an adjuvant to improve the immunogenicity of its tablet vaccine candidates.

Webull offers kinds of Vaxart Inc stock information, including NASDAQ:VXRT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VXRT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VXRT stock methods without spending real money on the virtual paper trading platform.